News coverage about Oxford Immunotec Global (NASDAQ:OXFD) has been trending positive on Tuesday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.4304402212754 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Oxford Immunotec Global (NASDAQ:OXFD) opened at $12.00 on Tuesday. The company has a market capitalization of $311.19, a PE ratio of -5.94 and a beta of -0.30. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global has a twelve month low of $10.00 and a twelve month high of $19.51.
Several research firms have recently commented on OXFD. Piper Jaffray Companies decreased their price objective on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a report on Tuesday, October 31st. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the stock a “buy” rating in a report on Monday, December 18th. BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research downgraded Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $20.00 price objective on shares of Oxford Immunotec Global in a report on Wednesday, November 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Oxford Immunotec Global currently has a consensus rating of “Hold” and an average target price of $18.75.
COPYRIGHT VIOLATION WARNING: This report was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3225243/positive-media-coverage-somewhat-unlikely-to-affect-oxford-immunotec-global-oxfd-stock-price.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.